Related Experiment Video
Updated: Jun 1, 2026
06:14
Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model
Published on: February 17, 2023
Phenytoin-induced gingival overgrowth
1Division of Pediatric Neurology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Acta Neurologica Scandinavica
|June 10, 2011
Summary
Folic acid supplementation significantly reduces the incidence of Phenytoin-induced gingival overgrowth (PIGO). This finding offers a promising, low-risk intervention for managing this common adverse effect of Phenytoin therapy.
Area of Science:
- Pharmacology
- Periodontology
- Medical Adverse Effects
Background:
- Phenytoin therapy commonly causes gingival overgrowth, impacting patient health and appearance.
- Poor oral hygiene exacerbates Phenytoin-induced gingival overgrowth (PIGO) severity.
- PIGO involves complex interactions of fibroblast biology, inflammation, and genetic factors.
Purpose of the Study:
- To investigate the efficacy of folic acid supplementation in preventing Phenytoin-induced gingival overgrowth (PIGO).
Main Methods:
- Review of existing evidence on Phenytoin-induced gingival overgrowth (PIGO) and its management.
- Analysis of the impact of folic acid supplementation on PIGO incidence.
Main Results:
- Folic acid supplementation demonstrates conclusive evidence in significantly decreasing the incidence of PIGO.
- This intervention offers a potential preventative measure against this adverse drug effect.
Conclusions:
- Folic acid supplementation is a highly effective strategy for reducing Phenytoin-induced gingival overgrowth (PIGO).
- This approach provides a valuable, evidence-based option for patients undergoing Phenytoin therapy.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...